Today, the screeners at HealthTechMovers.com picked up 3 HealthTech Stocks up over 49% past 10 days and have been added to our watchlist. These are very volatile stocks so please do your own research before you make any investments. While we list the ratings of various 3rd party services, we're not recommending these stocks and we're not paid by the featured tickers, we simply report the big movers. If the editor has a position, it will be noted below the charts.
PoliticsAndMyPortfolio.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
Ontrak, OTRK
Summary: Ontrak, Inc. is an AI and telehealth enabled, virtualized outpatient healthcare treatment company. The company's Predict-Recommend-Engage(TM) platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways. Ontrak, Inc., formerly known as Catasys Inc., is based in United States.
Recent OTRK Stock Price (approx 10:00am EST.): $1
Previous Close for OTRK Stock: $1.00
Percentage Price Change Past 10 Days for OTRK stock: +77%
TipRanks.com reports that Ontrak stock currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating for OTRK stock with an average price target is $2.50.
Click here to get the full story on OTRK stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.
Recent SVRA Stock Price (approx 10:00am EST.): $2.75
Previous Close for SVRA Stock: $2.67
Percentage Price Change Past 10 Days for SVRA stock: +50%
TipRanks.com reports that Savara stock currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating for SVRA stock with an average price target is $3.00.
Click here to get the full story on SVRA stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo Grove, United States.
Recent PHAT Stock Price (approx 10:00am EST.): $12.36
Previous Close for PHAT Stock: $11.58
Percentage Price Change Past 10 Days for PHAT stock: +49%
TipRanks.com reports that Phathom Pharmaceuticals stock currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating for PHAT stock with an average price target is $28.00.
Click here to get the full story on PHAT stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
The other great tool for charting is TradingView.com, so you might want to check that out too.
The information in this article was pulled from third part services. The prices listed above are not real-time and will be delayed at least 15 minutes.
PoliticsAndMyPortfolio.com keeps our subscribers informed of breaking news, reports, stock news or information that can have a positive or negative impact on their portfolio. We look at world events, political activity and the movement of stocks, bonds, metals, commodities and more to provide investors with timely information. Join thousands of investors who already signed up for our free subscription to PoliticsAndMyPortfolio.com.
